6MW-3211

N/A

Report date: 2026/05/07 20:00:36

Base Information

Drug Name6MW-3211
Drug Alias Name6MW32116MW-3211
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionCluster of differentiation 47 inhibitorsProgrammed death-ligand 1 blockers
TargetsCluster of differentiation 47Programmed death-ligand 1
Therapy Area/IndicationsMyelodysplastic SyndromesLung NeoplasmsCarcinoma, Renal Cell +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesMabwell (Shanghai) Bioscience Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesMabwell (Shanghai) Bioscience Co Ltd
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesCarcinoma, Renal CellLymphoma +[4] 
Inactive IndicationsLung NeoplasmsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A